Compare Levi Strauss & Co. (LEVI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Zimmer Biomet Holdings Inc — how do they compare? Levi Strauss & Co. trades at $24.39 (market cap $9.21B), while Zimmer Biomet Holdings Inc trades at $89.6 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Levi Strauss & Co. pays the higher dividend (2.68%). Which is the better fit depends on your goals.
| LEVI | ZBH | |
|---|---|---|
Market Cap | $9.21B | $17.36B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.99 | $107.71 |
52-Week Low | $17.92 | $79.58 |
Enterprise Value | $10.52B | $24.40B |
Dividend Yield | 2.68% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $24.03, down 1.35% over the past day, yet maintains a bullish technical trend with consistent earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.28, exceeding expectations of $0.24, and raised its full-year outlook. Strong fundamentals include a 61.72% gross margin and 9.66% net income margin, supported by a digital strategy driving direct-to-consumer growth. Analyst consensus is overwhelmingly bullish with an 83.33% buy rating and a $28.00 price target, implying significant upside from current levels.
Outlook remains positive given earnings momentum and dividend increases, but risks include tariff pressures and foreign exchange volatility noted in recent reports. The stock's valuation at a P/E of 17.4 appears reasonable relative to profitability, though competitive and macroeconomic headwinds warrant monitoring for sustained growth.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
